A new study from the Institute of Environmental Medicine (IMM), published in The Lancet Regional Health - Europe, shows that ...

Dazucorilant failed to slow disease progression in ALS patients in the DAZALS Phase 2 clinical trial, but may have extended ...

A new meta-analysis suggests that active exercise may slow functional decline in ALS, while noninvasive brain stimulation ...

Here is a look at the 10 most prominent lateral lawyer moves of 2024, compiled with input from a handful of legal industry ...

Neurizon has reported positive eight-month interim data from its open-label extension study in patients with ALS (motor ...

In the 60+ years that it's been on the air, the daytime ABC drama "General Hospital" has brought attention to an array of ...

The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Maxim downgraded NeuroSense (NRSN) to Hold from Buy. The firm cites the company having received feedback from the FDA regarding the Phase trial 3 design for PrimeC to treat amyotrophic lateral ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...